|
|
Post by otherottawaguy on May 8, 2017 9:56:12 GMT -5
Full questions will be posted below for the questions in the poll. Max 4 votes each. Commentary is allowed. Poll closes the Mon before the ASM. |
|
|
|
Post by otherottawaguy on May 8, 2017 9:58:45 GMT -5
| Author | Thumb Ups | question | | Silentnight | 12 | see below using author | | dq1111 | 11 | | | slugworth008 | 9 | | | wkk | 8 | | | silentknight | 8 | | | sportsranchero | 8 | | | wkk01 | 7 | | | peppy | 7 | | | nylefty | 7 | | | petech | 7 | |
|
|
|
|
Post by otherottawaguy on May 8, 2017 10:02:43 GMT -5
silentknight 12 Do you believe that any of the blame of the extreme erosion of shareholder value rests with management and the Board of Directors? Why or why not? ----
dg1111 11 Given that the cash on hand is getting lower and Afrezza sales are not increasing at a fast enough rate to generate cash in the near term, what is the company's plan to continue to operate past the current cash runway? ----
sugworth008 9 Where is the uptick in scripts as referenced in the last CC? ----
wkk01 8 Last year foreign approval was discussed, so far the only progress shown has been a list of potential candidates, what is the current status of potential foreign approval? ----
silentknight 8 Can you how explain how exorbitant salaries for management officials and Board of Directors are justified while MNKD's market cap and shareholder value have sunk to all-time lows? ----
sportsrancho 8 How much conflict is there between the BOD, the AEMF, and management, on how to move the company forward ----
wkk01 7 How many countries have had submission paperwork presented, what are the anticipated dates for approval? ----
peppy 7 What is the plan to stay alive as an entity? ----
nylety 7 Isn't it time to drastically lower the price of Afrezza in order to not only boost sales but also to get some badly-needed positive publicity? ----
petech 7 From the embarrassment of publicly disclosing DeSisto as the new CEO only to realize he had a non-compete, to the year-long plus partnership with Sanofi where we seemingly sat on our hands and never thought to raise capital despite knowing Sanofi and you were not on the same page, to the year-long plus since we've gotten back Afrezza and have waivered from contract sales force to in house sales force etc., it seems unfortunately clear that foresight is at a premium with MNKD. Can you provide us with guidance as to what sales numbers you intend to hit this year (and next), when you are going to hit them, and what you are going to do to fund operations until this point? In the past, I've accepted the "competitive reasons to not disclose" excuse but I am all but convinced there is no plan and it is leading by reaction rather than strategically
|
|
|
|
Post by peppy on May 9, 2017 10:02:33 GMT -5
of the questions written, in this moment, I go with a version of my question.
What is the plan to stay alive as an entity? (The cash plan.)
It is a broad question. It could cover international expansion if they want to talk about that. Then I would expect the trial, label change, insurance, an excellent product and the sales team, physician acceptance.
hopefully the question will be answered before questions and answers.
|
|
|
|
Post by lakon on May 9, 2017 14:19:42 GMT -5
otherottawaguy, I thought that we had 7 days until the 10th to post our questions, but the original thread is locked. It appears that you have moved on to polling already. Here are my, apparently, late breaking write-in questions. I hope they are just-in-time to garner attention worthy of your poll. Thanks for all the hard work. lakon #1: Will MNKD pursue non-dilutive alternative financing options, such as rights offerings and/or debt offerings directly to shareholders? lakon #2: Is the BoD, in general, and Chairman, specifically, willing and able to commit to turning this company around, even if it means a personal commitment of time and resources, including, but not limited to capital? If any member of the Board does not feel that they can give it their all with full engagement for any reason, would they be willing to find a suitable replacement over the next year? (With all due respect to Chairman Kresa, given his professional and personal relationship with Al Mann, his extensive turnaround experience as the longest serving CEO in the defense industry while at Northrop Grumman, and his interim Chairman role at GM in finding new leadership there, what is your level of commitment to MNKD? What do you feel can be done to accelerate success? For many reasons, it is understandable why you may only commit limited resources to MNKD, and it would be unfair to expect a similar kind of commitment that Al Mann gave. Yet, the company needs a point man with vast experience and contacts to sell the story again. Would you be willing to commit to finding such a person if it cannot be you? MNKD has made technical and medical achievements that no one has in over 90 years. Few medical professionals, let alone patients, seem to realize the Herculean feats achieved. What is the BoD's, and especially Chairman's, view of what's wrong and how to fix it?)
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 9, 2017 14:24:36 GMT -5
I think some of these questions are pointless. I am not sure why it matters whose fault it is Re: MNKD or Board. Does anyone expect them to throw each other under the bus?
I think the only question is why are you not selling the drug? You gave xyz excuse and now that no longer holds weight, you gave abc excuse and now that no longer holds weight. What is the reason for such a large fallout?
|
|
|
|
Post by otherottawaguy on May 14, 2017 12:20:53 GMT -5
Last chance to vote, poll locks at midnight.
|
|
|
|
Post by peppy on May 14, 2017 13:33:54 GMT -5
Last chance to vote, poll locks at midnight. My new votes for questions.
What is the company's plan to generate cash in the near term and post current runway?
How many countries have approval paper work been submitted for? Dates past and upcoming?
Please provide guidance as to what sales numbers you intend to hit this year and when you are going?
What is the plan to stay alive as an entity?
Thanks OOG.
|
|
|
|
Post by scoy on May 14, 2017 14:04:32 GMT -5
More people want to attribute blame than want to solve problems?
What percentage of people who try Afrezza are still using it 6 (or 12) months later?
What can, and is, being done to raise that percentage?
This is the only person who is thinking of solving a problem (Kudos to them!): When would mgmt consider lower the price of Afrezza to garner free publicity and an increasing TRx
|
|
|
|
Post by cjm18 on May 14, 2017 14:16:52 GMT -5
When will epipen be fully approved by FDA.
What are profit margins for a prescription in international market vs USA.
Refill rate hurt by rebate program? 1st rx was almost free but 2nd wasn't covered by insurance?
Why didn't the big prescribing doctors come back.
|
|
|
|
Post by tchalaa on May 14, 2017 14:35:01 GMT -5
Where are we with the label 'Ultra rapid insulin' is it already approved, since it is been used?
|
|
